These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31735308)

  • 41. International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation.
    Suarez J; Piccini JP; Liang L; Atherton JJ; Hayward CS; Krum H; Fonarow GC; Lopes RD; Hernandez AF
    Am Heart J; 2012 May; 163(5):804-11. PubMed ID: 22607858
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long‑term prevention of thromboembolic complications in patients with atrial fibrillation?
    Riva N; Lip GY
    Pol Arch Med Wewn; 2012; 122(1-2):45-53. PubMed ID: 22353706
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Atrial Fibrillation and Stroke: Making Sense of Recent Observations on Anticoagulation.
    Proietti M; Lip GY
    Cardiol Clin; 2016 May; 34(2):317-28. PubMed ID: 27150180
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
    Kirchhof P; Blank BF; Calvert M; Camm AJ; Chlouverakis G; Diener HC; Goette A; Huening A; Lip GYH; Simantirakis E; Vardas P
    Am Heart J; 2017 Aug; 190():12-18. PubMed ID: 28760205
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB; Halperin JL
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How to define valvular atrial fibrillation?
    Fauchier L; Philippart R; Clementy N; Bourguignon T; Angoulvant D; Ivanes F; Babuty D; Bernard A
    Arch Cardiovasc Dis; 2015 Oct; 108(10):530-9. PubMed ID: 26184867
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program.
    Mazurek M; Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Zint K; França LR; Lu S; Lip GYH;
    Am J Med; 2018 Aug; 131(8):945-955.e3. PubMed ID: 29654720
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anticoagulants for stroke prevention in heart failure with reduced ejection fraction.
    Schäfer A; Flierl U; Bauersachs J
    Clin Res Cardiol; 2022 Jan; 111(1):1-13. PubMed ID: 34448932
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antithrombotics in atrial fibrillation and coronary disease.
    Velagapudi P; Turagam MK; Agrawal H; Mittal M; Kocheril AG; Aggarwal K
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):977-86. PubMed ID: 25046150
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation?
    Lip GY
    J R Coll Physicians Edinb; 2012; 42 Suppl 18():35-44. PubMed ID: 22518392
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Stroke prophylaxis in atrial fibrillation : When, how and for whom?].
    Maurer T; Sohns C
    Herz; 2017 Jun; 42(4):373-379. PubMed ID: 28439617
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anticoagulation in atrial fibrillation.
    Anderson M; Kirk M
    Med Health R I; 2004 Apr; 87(4):98-100. PubMed ID: 15168633
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015.
    Alamneh EA; Chalmers L; Bereznicki LR
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28177198
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
    Deedwania PC; Huang GW
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):265-75. PubMed ID: 21740079
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preventing Thrombosis to Improve Outcomes in Heart Failure Patients.
    Shantsila E; Lip GY
    Prog Cardiovasc Dis; 2016; 58(4):386-92. PubMed ID: 26433062
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Antithrombotic treatment of patients with valvular atrial fibrillation].
    Bovin A; Christensen TD; Grove EL
    Ugeskr Laeger; 2017 Jul; 179(29):. PubMed ID: 28789760
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
    Kornej J; Potpara T; Lip GY
    Pol Arch Med Wewn; 2013; 123(11):623-34. PubMed ID: 24104195
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Will warfarin soon be passé? New approaches to stroke prevention in atrial fibrillation.
    Hammwöhner M; Goette A
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):18-27. PubMed ID: 18594479
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]).
    Cherian TS; Shrader P; Fonarow GC; Allen LA; Piccini JP; Peterson ED; Thomas L; Kowey PR; Gersh BJ; Mahaffey KW
    Am J Cardiol; 2017 Jun; 119(11):1763-1769. PubMed ID: 28416199
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Nationwide Cohort Study.
    Jung H; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
    Chest; 2019 Feb; 155(2):354-363. PubMed ID: 30472021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.